Fiche société
Memorial Sloan Kettering Cancer Center
Traitements, essais et publications liés.
Traitements25programmes
Essais19liés
Publications15liées
SourceDBlocale
Traitements
25| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| CryoablationThe FDA has granted marketing authorization for the ProSense® Cryoablation System for the local treatment of patients aged 70 years or older with low-risk early-stage breast cancer who are also receiving adjuvant hormone therapy. This clinical trial is designed to collect additional data on the safety and effectiveness of cryoablation when used as part of routine clinical care. Specifically, the study will evaluate recurrence rates following the procedure for up to 5 years post-treatment. In addition, linkage to claims data will be used to assess long-term outcomes, including breast cancer-related surgeries, mammograms and other breast imaging procedures, breast biopsies, and all-cause mortality. | Cancer | Phase 1 | Ablation tumorale non thermique | United States | Dispositif/procédure : résultats à interpréter par essai et indication. |
| focal cryotherapyThe purpose of this study is to find out if men, with low-risk prostate, can have the small amount of cancer within their prostate removed by freezing, called Focal Cryoablation or Cryotherapy. | Cancer | Phase 2 | À vérifier | United States | À vérifier |
| infusion of melphalan and dactinomycinThe purpose of this study is to find out whether giving the study drug pembrolizumab in combination with the chemotherapy drugs melphalan and dactinomycin, delivered directly to the affected arm or leg using a technique called isolated limb infusion (ILI), is a safe treatment that can delay the time before your disease gets worse (progresses). | Cancer | Phase 2 | À vérifier | United States | À vérifier |
| Isolated Limb InfusionThe purpose of this study is to find out whether giving the study drug pembrolizumab in combination with the chemotherapy drugs melphalan and dactinomycin, delivered directly to the affected arm or leg using a technique called isolated limb infusion (ILI), is a safe treatment that can delay the time before your disease gets worse (progresses). | Cancer | Phase 2 | À vérifier | United States | À vérifier |
| LorlatinibThis study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this dose, they can test it in future participants to see if it is effective in treating their metastatic ALK-rearranged NSCLC. The researchers are also looking to see whether there are specific genes or DNA sequences associated with a response to treatment with lorlatinib and ramucirumab. | Cancer | Phase 1 | À vérifier | United States | À vérifier |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Cancer, Parkinson | Phase 1 | Ablation tumorale non thermique | United States | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 3 | Ablation tumorale non thermique | United States, Australia, Austria, Canada, Hungary, Italy, Japan, Poland, Portugal, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 3 | Ablation tumorale non thermique | United States, Argentina, Australia, Canada, China, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Netherlands, Poland, Russia, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom | Dispositif/procédure : résultats à interpréter par essai et indication. |
| Isolated Limb InfusionThe purpose of this study is to find out whether giving the study drug pembrolizumab in combination with the chemotherapy drugs melphalan and dactinomycin, delivered directly to the affected arm or leg using a technique called isolated limb infusion (ILI), is a safe treatment that can delay the time before your disease gets worse (progresses). | Cancer | Phase 2 | À vérifier | United States | À vérifier |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 1/2 | Ablation tumorale non thermique | United States, Australia, France, Israel, Italy, South Africa, Switzerland | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 2 | Ablation tumorale non thermique | United States, Austria, Canada, Hungary, Israel, Italy, Poland, Russia, South Korea, Spain, Switzerland | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 3 | Ablation tumorale non thermique | United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, … | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 1/2 | Ablation tumorale non thermique | United States, Brazil, Chile, China, France, Germany, Italy, Norway, South Korea, Switzerland, Taiwan, Thailand | Dispositif/procédure : résultats à interpréter par essai et indication. |
| LorlatinibThis study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this dose, they can test it in future participants to see if it is effective in treating their metastatic ALK-rearranged NSCLC. The researchers are also looking to see whether there are specific genes or DNA sequences associated with a response to treatment with lorlatinib and ramucirumab. | Cancer | Phase 1 | À vérifier | United States | À vérifier |
| focal cryotherapyThe purpose of this study is to find out if men, with low-risk prostate, can have the small amount of cancer within their prostate removed by freezing, called Focal Cryoablation or Cryotherapy. | Cancer | Phase 2 | À vérifier | United States | À vérifier |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 3 | Ablation tumorale non thermique | United States, Argentina, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Mexico, Philippines, … | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 3 | Ablation tumorale non thermique | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, … | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Cancer | Phase 3 | Ablation tumorale non thermique | United States, Australia, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Guatemala, Hungary, Ireland, Italy, Japan, Malaysia, Mexico, … | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Cancer | Phase 2 | Ablation tumorale non thermique | Brazil | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 3 | Ablation tumorale non thermique | United States, Australia, Brazil, Chile, China, France, Germany, Guatemala, Ireland, Israel, Italy, Japan, New Zealand, Poland, Russia, South Korea, Spain, Turkey (Türkiye), Ukraine, United Kingdom | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 1/2 | Ablation tumorale non thermique | United States, Hungary, Israel, Italy, Poland, South Korea, Spain, Taiwan, Ukraine | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Cancer | Phase 3 | Ablation tumorale non thermique | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Malaysia, … | Dispositif/procédure : résultats à interpréter par essai et indication. |
| CryoablationThe FDA has granted marketing authorization for the ProSense® Cryoablation System for the local treatment of patients aged 70 years or older with low-risk early-stage breast cancer who are also receiving adjuvant hormone therapy. This clinical trial is designed to collect additional data on the safety and effectiveness of cryoablation when used as part of routine clinical care. Specifically, the study will evaluate recurrence rates following the procedure for up to 5 years post-treatment. In addition, linkage to claims data will be used to assess long-term outcomes, including breast cancer-related surgeries, mammograms and other breast imaging procedures, breast biopsies, and all-cause mortality. | Cancer | Non applicable | Ablation tumorale non thermique | United States | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Parkinson | Phase 2 | Ablation tumorale non thermique | United States, Canada, Chile, Colombia, France, Germany, Hungary, Ireland, Japan, Poland, South Korea, Spain, Taiwan, Ukraine, United Kingdom | Dispositif/procédure : résultats à interpréter par essai et indication. |
| PembrolizumabThe purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). | Cancer | Phase 1 | Ablation tumorale non thermique | United States | Dispositif/procédure : résultats à interpréter par essai et indication. |
Essais cliniques
19| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Pembrolizumab | Cancer | Phase 1 | NCT06246968 | A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer | RECRUITING |
| Pembrolizumab | Parkinson | Phase 2 | NCT04191135 | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) | TERMINATED |
| Cryoablation | Cancer | Non applicable | NCT07629206 | Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial) | RECRUITING |
| Pembrolizumab | Cancer | Phase 3 | NCT06393374 | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 1/2 | NCT04165070 | KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT03615326 | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | COMPLETED |
| Pembrolizumab | Cancer | Phase 2 | NCT06822543 | TROPICAL-1 — A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer) | RECRUITING |
| Pembrolizumab | Cancer | Phase 3 | NCT04736706 | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) | ACTIVE_NOT_RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT06952504 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT07216703 | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) | RECRUITING |
| focal cryotherapy | Cancer | Phase 2 | NCT00774436 | Study of Focal Cryoablation in Low-Risk Prostate Cancer | COMPLETED |
| Lorlatinib | Cancer | Phase 1 | NCT06007937 | A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer | ACTIVE_NOT_RECRUITING |
| Pembrolizumab | Parkinson | Phase 1/2 | NCT06469944 | Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT06623422 | A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | RECRUITING |
| Pembrolizumab | Parkinson | Phase 2 | NCT04924101 | Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) | COMPLETED |
| Pembrolizumab | Parkinson | Phase 1/2 | NCT04305041 | Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) | COMPLETED |
| Isolated Limb Infusion | Cancer | Phase 2 | NCT04332874 | A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg | RECRUITING |
| Pembrolizumab | Parkinson | Phase 3 | NCT03898180 | Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) | COMPLETED |
| Pembrolizumab | Parkinson | Phase 3 | NCT03358472 | Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) | COMPLETED |
Publications
15| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| focal cryotherapy | Focal Cryotherapy in Prostate Cancer. Does Gleason Impact Results? | International braz j urol : official journal of the Brazilian Society of Urology | ||
| focal cryotherapy | Differential Cytokine Profiles in Prostate Cancer Under Treatment: Implications for Prognosis and Synergistic Therapy Design. | Cancers | ||
| Lorlatinib | Cost-effectiveness analysis of lorlatinib as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in Italy. | Journal of medical economics | ||
| Lorlatinib | Cost of managing brain metastases in patients with ALK+ advanced NSCLC with first-line tyrosine kinase inhibitors in the UK. | Lung cancer management | ||
| Lorlatinib | Clinical characteristics of ALK-positive NSCLC patients treated with sequential ALK-TKI therapies in a single-centre. | Lung cancer management | ||
| infusion of melphalan and dactinomycin | International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients. | Annals of surgical oncology | ||
| infusion of melphalan and dactinomycin | Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology | ||
| infusion of melphalan and dactinomycin | Isolated Limb Infusion for Limb-Threatening Sarcomas. | Annals of surgical oncology | ||
| Isolated Limb Infusion | Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver. | Clinical & experimental metastasis | ||
| Isolated Limb Infusion | Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | ||
| Isolated Limb Infusion | A Percutaneous, High-Flow, Hyperthermic Isolated Limb Perfusion Technique for Extremity Malignancies: Point of Technique. | Journal of surgical oncology | ||
| Pembrolizumab | Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC). | Oncoimmunology | ||
| Pembrolizumab | Immunotherapy in the Treatment of Soft Tissue Sarcoma Since SARC028: An NCDB Analysis. | Journal of surgical oncology | ||
| Pembrolizumab | Cost-effectiveness of pembrolizumab as neoadjuvant therapy and in combination with standard of care (SOC) as adjuvant therapy for stage III-IVA resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC) in Switzerland. | Journal of medical economics | ||
| Pembrolizumab | C-reactive protein at pembrolizumab initiation and its trajectory from first-line chemotherapy as prognostic markers in metastatic urothelial carcinoma (YUSHIMA study). | International urology and nephrology |